Chris Sheldon | Head of Investor Relations |
Pascal Soriot | CEO & Executive Director |
Aradhana Sarin | CFO & Executive Director |
David Fredrickson | Executive Vice-President of Oncology Business Unit |
Susan Galbraith | EVP of Oncology Research & Development |
Ruud Dobber | Executive Vice-President of BioPharmaceuticals Business Unit |
Menelas Pangalos | EVP of BioPharmaceuticals R&D |
Marc Dunoyer | CEO of Alexion |
Leon Wang | Executive VP of International & China President |
Timothy Anderson | Wolfe Research |
Simon Baker | Redburn |
Sachin Jain | BofA Securities |
James Gordon | JPMorgan |
Mark Purcell | Morgan Stanley |
Stephen Scala | Cowen and Company |
Richard Parkes | BNP Paribas Exane |
Emmanuel Papadakis | Deutsche Bank |
Keyur Parekh | Goldman Sachs |
Jo Walton | Credit Suisse |
Michael Leuchten | UBS |
Luisa Hector | Berenberg |
Peter Welford | Jefferies |
Seamus Fernandez | Guggenheim |
Viktor Sundberg | Nordea Markets |
Thank you, Martin, and good afternoon, everybody. I'm Chris Sheldon, Head of Investor Relations at AstraZeneca. I'm pleased to welcome you to AstraZeneca's Full Year 2021 Conference Call. All materials presented are available on our website, and Slide 2 has the usual safe harbor statements. We'll be making comments on our performance using constant exchange rates, or CER, core financial numbers and other non-GAAP measures.